J&J, Wellcome Trust, Academics To Research Dengue Therapies

“Johnson & Johnson is joining the hunt for drugs to treat dengue fever — the world’s fastest-spreading tropical disease — by linking with academic researchers in Belgium and the Wellcome Trust medical charity,” Reuters reports. “The tie-up between J&J’s Janssen unit and researchers at the University of Leuven, who have received backing from Wellcome, will build on the discovery of a series of chemical compounds that are highly potent in preventing the replication of dengue virus,” for which there is no treatment or vaccine, according to the news agency. “Experts estimated in April that there may be as many as 390 million dengue infections around the world each year, although not all patients get seriously sick,” Reuters notes (Hirschler, 8/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.